Twenty-nine years after JonBenét Ramsey was found dead in her family's Colorado home, her father tells the Daily Mail he is ...

Twenty-nine years after JonBenét Ramsey was found dead in her family's Colorado home, her father tells the Daily Mail he is ...

Hansa Biopharma AB, ("Hansa" or "the Company"), , today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imlifidase. The Company is ...

The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patientsImlifidase is an enzyme that rapidly and efficiently cleaves all types ...

Hansa Biopharma AB ( ($SE:HNSA) ) has issued an update. Hansa Biopharma AB announced that CEO Renée Aguiar-Lucander will present at J.P. Morgan’s ...

Enrollment in the SAFEGUARD trial is ongoing at multiple centers globallyCompany on-track to share Phase 2b data in 2H 2027MIAMI, Dec. 18, 2025 ...

Jeffrey V. Ravetch (left) and Andrew T. Jones (right) showed that the anti-inflammatory activity of IgG is enhanced by co-engagement of type I and II ...

Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, ...

Immunoglobulin M has other functions beyond antibody class switching that have implications in asthma treatment.

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market ...

Immunoglobulin A (IgA) deficiency is the most common primary immunodeficiency in humans. It can increase the risk of allergies, asthma, and autoimmune disease. Primary immunodeficiencies are ...